Key Highlights
- Verici Dx plc (LSE:VRCI) shares rose 7.14% on 2 October 2026.
- Tutivia testing Revenue grew 53% year on year in the first half of 2026.
- 35 US transplant centres now use Tutivia, representing about 23% of annual US kidney transplants.
- The company launched a proposed Equity fundraise using AIM's Capital Access Window, with trading paused from 1 October pending the outcome.
- A new genetic test, TranscripTx, is due to launch in the fourth quarter of 2026.
Verici Dx Climbs on Growth and Funding News
Verici Dx plc (LSE:VRCI), the developer of advanced clinical diagnostics for organ transplant, saw its shares rise 7.14% on 2 October 2026. The move followed a busy few days in which the company published interim results showing strong commercial growth and launched a new equity fundraise to support its expansion plans.
Why Verici Dx Is in Focus
On 30 September Verici released unaudited interim results for the six months to 30 June 2026. Tutivia, its blood test designed to help detect early acute rejection after kidney transplant, delivered testing revenue growth of 53% year on year. The number of US transplant centres using Tutivia has risen to 35, representing about 23% of annual US kidney transplants, up from 29 centres covering around 20% at the time of its full-year results.
Management said three of the recently added centres had already moved to high recurring ordering, an important sign that adoption is becoming embedded in clinical practice. The company has a team of Business development directors led by a recently appointed senior commercial leader.
Alongside the results, Verici announced a proposed equity fundraise with institutional and other investors, run by Singer Capital Markets and Oberon Investments as joint bookrunners. The company elected to use AIM's Capital Access Window, meaning trading in its shares was paused from 7.30am on 1 October 2026 until the outcome is announced. The board said it had been greatly encouraged by support from key shareholders.
Key Reasons Behind the 7.14% Gain on 2 October 2026
Strong Tutivia momentum: Revenue growth of 53% and rising US centre adoption support the view that Verici is building a genuine commercial franchise.
Funding visibility: The company's cash runway had been expected to extend only to the end of 2026, so a successful raise removes a major uncertainty for LSE:VRCI.
Shareholder backing: Management's comments about key Shareholder support signalled that the fundraise was likely to attract demand.
New product pipeline: In September Verici announced it will launch TranscripTx, a next-generation sequencing test that measures genetic variants in blood RNA to help assess how transplant recipients respond to therapy and their risk of graft failure.
Partnerships: An August agreement to become a certified service provider for Olink adds a further revenue avenue.
Verici's Product Portfolio
Verici's tests are built on RNA signatures that capture immune response and biological pathways critical to transplant outcomes. Tutivia is the lead commercial product. PTRA, which assesses pre-transplant risk, is licensed to Thermo Fisher Scientific, and a clinical validation study was published in 2026. Protega is a longer-term fibrosis monitoring test. The company's US laboratory is CLIA-certified and CAP-accredited and received New York State clinical lab certification in June 2026. Chief executive Sara Barrington has described TranscripTx as translating cutting-edge RNA science into actionable intelligence.
Risks Investors Should Weigh
Verici remains loss-making and dependent on equity funding, and repeated raises at low prices dilute existing shareholders. Reimbursement timing in the US healthcare system can delay revenue recognition. Competition in transplant diagnostics is significant, and adoption must continue to accelerate to justify the Investment case.
Outlook for Verici Dx
Investors will watch for the formal result of the fundraise, the launch of TranscripTx in the fourth quarter and further growth in ordering centres. Management has previously cited a long-term revenue ambition of around £60 million a year. If Tutivia adoption keeps building, Verici Dx (LSE:VRCI) could move meaningfully closer to cash breakeven.






Please wait processing your request...